HOME >> BIOLOGY >> NEWS
Use of aspirin or other NSAIDs increases survival

Regular use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) seems to reduce the risk of developing various cancers, including prostate cancer. Now it appears that such drugs may help men with prostate cancer live longer, according to a Fox Chase Cancer Center study presented today at the 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology in Atlanta, Ga.

"NSAIDs have been associated with reductions in the risk of developing various gastrointestinal cancers and improvement in their treatment outcomes," said the study's lead author, Fox Chase radiation oncologist Khanh H. Nguyen, M.D. "However, any impact NSAIDs may have on treatment for prostate cancer has been unclear. We wanted to see if patients who used these drugs regularly before their diagnosis and treatment gained any benefit."

The Fox Chase study involved 1,206 men who had definitive radiation therapy for localized prostate cancer. The researchers compared long-term treatment outcomes of 232 patients who had used NSAIDs regularly before treatment with the outcomes of the 974 men with no history of regular NSAID use. Other characteristics, such as smoking, were balanced between the two groups. The follow-up period averaged more than four and a half years.

"Pretreatment NSAID use was associated with significant delays in distant metastases, decreased rates of second cancers and improvement in overall survival," Nguyen said. "Our data suggest a potential benefit of NSAIDs in managing prostate cancer."

NSAID use remained an independent predictor for improved overall survival, even after taking into account other variables such as age, Gleason score and radiation dose.

Laboratory studies have suggested that by inhibiting the COX-1 and COX-2 enzymes, NSAIDs may enhance programmed cell death (apoptosis) and inhibit the development of blood vessels (angiogenesis) that feed a tumor. The Fox Chase researchers concluded that in
'"/>

Contact: Colleen Kirsch
colleen.kirsch@fccc.edu
215-306-1211
Fox Chase Cancer Center
4-Oct-2004


Page: 1 2

Related biology news :

1. Study to look at aspirin as aid to conception, healthy pregnancy
2. Exercise, aspirin consumption and childbirth may alter cancer risk
3. Genetic variation impacts aspirins effectiveness in preventing colon cancer, Dartmouth study finds
4. Fighting cancer with aspirin?
5. Ovarian cancer responds to aspirin derivative with chemo
6. Pretreating rogue cancer cells with aspirin cripples their resistance to targeted therapy
7. Study supports use of aspirin in treating pregnancy disorder
8. Birthing a new model of aspirin therapy in preeclampsia
9. Study finds gender differences in renal and other genes contributing to blood pressure
10. Pregnant mothers join search for causes of autism
11. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2020)... (PRWEB) , ... August 19, 2020 , ... ... the premier conference and expo uniting life science, data science, informatics and IT ... sessions. , “In this period of uncertainty and change, Bio-IT takes the leadership ...
(Date:8/12/2020)... SOUTHFIELD, Mich. (PRWEB) , ... August 11, 2020 ... ... Janssen R&D subsidiary based in Princeton, NJ, have entered into license agreements with ... discovery and development. Both Roche and J&J have annual Research and Development ...
(Date:8/7/2020)... ... August 06, 2020 , ... Alucio™, a fast-growing ... that Eric Chen and Jessica Wong have joined the company’s leadership team as ... , Eric Chen heads development efforts for Alucio’s flagship product, Beacon, an innovative ...
Breaking Biology News(10 mins):
(Date:8/15/2020)... SCOTTSDALE, Ariz. (PRWEB) , ... August 13, 2020 ... ... 4254 on its annual Inc. 5000 list, the most prestigious ranking of the ... successful companies within the American economy’s most dynamic segment—its independent small businesses. Intuit, ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... is making available for free its new white paper – Simulated Transport ... testing into today’s biologics licensing application (BLA). In response, Modality Solutions shares ...
(Date:8/7/2020)... ... August 06, 2020 , ... VGXI, a ... has closed on the purchase of greenfield for a new, expanded manufacturing facility. ... over 21 acres in the initial acquisition, with an option to purchase an ...
(Date:8/3/2020)... ... 2020 , ... Introducing Ardent Animal Health – MediVet Biologics rebrands company and ... Known as MediVet Biologics since its formation in 2016, the company is relaunching itself ... will build on its base of innovative therapies for osteoarthritis and cancer. ...
Breaking Biology Technology:
Cached News: